Indo Us Biotech Limited (INDOUS)

About

Indo Us Biotech Limited operates in agricultural products within Consumer Staples, with a market capitalisation of ₹170 crore and recent quarterly revenues of ₹22–33 crore. It is 68% promoter-owned with minimal institutional participation (FII 0.01%, DII 0%). The company achieved profitability with 23%+ operating margins in 2024, though recent quarters show material margin and earnings deterioration.

Face value: ₹10

Market cap

₹154 Cr

P/E

13.5×

P/B

1.7×

Dividend yield

0.3%

ROE

15.3%

ROCE

18.5%

Debt / equity

0.4

OPM

15.4%

EPS (TTM)

₹5.7

Book value

₹46.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin compression from 23.51% in Dec 2024 to 12.03% in Jun 2026 signals cost pressures or pricing headwinds; identify whether input inflation, product mix, or competitive pricing is driving this deterioration.
Profitability collapse: net profit fell from ₹5.06 crore (Dec 2024) to ₹1.97 crore (Mar 2026) before partial recovery to ₹3.04 crore (Jun 2026), still 40% below 2024 peak.
Revenue volatility: quarterly revenues swing from ₹22.17–₹33.38 crore over 18 months; verify whether this reflects seasonal patterns, working-capital constraints, or underlying demand instability.
Illiquid shareholder base: FII at 0.01% and DII at 0% limit independent governance oversight; verify related-party transactions, capital allocation, and exit liquidity for public shareholders.

Generated analysis · source review pending

Growth drivers

Operating-margin recovery from 12.03% (Jun 2026) to 23%+ levels achieved in Dec 2024 would multiply profitability from current revenue base; identify what operational or cost-management changes would enable restoration.
Recent quarter (Jun 2026) reached ₹32.99 crore revenue, approaching historical peaks; sustaining this level would provide a stable foundation for earnings recovery if operational margins stabilise.
Debt-to-equity ratio of 0.4 provides capital deployment flexibility; verify whether management has identified growth capex, capacity expansion, or working-capital initiatives.
Virtually absent institutional participation (FII 0.01%, DII 0%) means any stabilisation in profitability could attract domestic and foreign institutional capital, providing upside re-rating specific to this illiquid micro-cap.

Generated analysis · source review pending

1,503 historical price candles were omitted because the exchange source has not been verified.

₹76.8-0.9%1Y

Quick read

rule-based

Pros

+High promoter holding of 68.3% with no pledge

Cons

−Low dividend payout of 4.4% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

51/100

Business quality: 49
Growth: 20
Valuation: 83

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Lt Foods LimitedLTFOODSLTFOODS	₹13,862 Cr	₹14,836 Cr	₹11,633 Cr	₹1,247 Cr	10.6%	₹640 Cr	5.7%	20.1%	14.9%	176
Krbl LimitedKRBLKRBL	₹8,604 Cr	₹8,774 Cr	₹6,009 Cr	₹992 Cr	14.8%	₹758 Cr	10.6%	15.5%	11.7%	323
Gujarat Ambuja Exports LimitedGAELGAEL	₹7,233 Cr	₹7,667 Cr	₹6,032 Cr	₹602 Cr	8.1%	₹416 Cr	5.3%	13.2%	9.7%	84
Trualt Bioenergy LimitedTRUALTTRUALT	₹3,812 Cr	₹5,458 Cr	₹2,051 Cr	₹381 Cr	16.8%	₹149 Cr	5.6%	10.8%	6.3%	170
Kaveri Seed Company LimitedKSCLKSCL	₹3,676 Cr	₹3,676 Cr	₹1,279 Cr	₹292 Cr	24.2%	₹250 Cr	21.2%	18.2%	18.2%	396
Amir Chand Jagdish Kumar (Exports) LimitedAEROPLANEAEROPLANE	₹2,156 Cr	₹2,914 Cr	₹2,287 Cr	₹225 Cr	9.9%	₹103 Cr	4.5%	24.1%	11.2%	253
Sanstar LimitedSANSTARSANSTAR	₹2,063 Cr	₹2,083 Cr	₹821 Cr	₹54 Cr	4.8%	₹44 Cr	4.4%	5.5%	5.1%	53
Grm Overseas LimitedGRMOVERGRMOVER	₹1,613 Cr	₹1,979 Cr	₹1,869 Cr	₹102 Cr	5.1%	₹77 Cr	4.2%	23.7%	14.5%	212
Chaman Lal Setia Exports LimitedCLSELCLSEL	₹1,401 Cr	₹1,484 Cr	₹1,478 Cr	₹171 Cr	10.9%	₹125 Cr	8%	19%	14.6%	197
Avt Natural Products LimitedAVTNPLAVTNPL	₹1,338 Cr	₹1,452 Cr	₹822 Cr	₹114 Cr	12.6%	₹84 Cr	9.1%	16.9%	12.2%	327
Gulshan Polyols LimitedGULPOLYGULPOLY	₹1,009 Cr	₹1,401 Cr	₹2,260 Cr	₹134 Cr	4.7%	₹43 Cr	1.2%	7.5%	4.1%	49
Regaal Resources LimitedREGAALREGAAL	₹883 Cr	₹1,493 Cr	₹1,090 Cr	₹133 Cr	11.2%	₹60 Cr	4.9%	15%	15.2%	50

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	73	104	110
COGS	-20	73	80
Gross profit	—	31	30
	82	12	13
	11	19	17
OPM %	14.8%	18.2%	15.4%
Depreciation	1	1	1
Interest	2	1	2
	0	0	0
Profit before tax	9	17	14
Tax	1	0	1
Tax %	6.3%	1.6%	5.8%
	8	16	13
PAT margin %	11.3%	15.7%	11.9%
EPS (₹)	—	8.1	6.5
EPS adjusted (₹)	4.1	8.1	6.5
	—	3.1%	—
Annual report	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2024	Mar 2025	Mar 2026
Equity capital	20	20	20
Reserves	43	58	72
	14	15	37
	7	4	4
Total equity & liabilities	84	98	133
	7	10	11
CWIP	4	—	1
Investments	0	0	0
	74	88	121
Total assets	84	98	133

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	2	-1	-16
	-3	-1	3
	1	-1	24
Net cash flow	1	-4	12
Free cash flow	-0	-1	-19
CFO / Operating profit %	20.6%	-7.5%	-94.6%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 6%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: -19%

Return on equity

7 years: —
5 years: —
3 years: 16%
Last year: 14%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	30%	27.3%
EBITDA margin %	14.8%	18.2%	15.4%
EBIT margin %	13.7%	17.2%	14.6%
PAT margin %	11.3%	15.7%	11.9%
Working capital
Receivable days	95	53	45
Inventory days	304	355	454
Payable days	26	6	2
NWC days	374	402	498
Leverage
Current ratio	3.88	5.31	3.05
Debt to EBITDA	1.33	0.78	2.18
Debt to equity	0.23	0.19	0.4
Interest coverage	6.8	12.1	7.2
Asset turnover	0.86	1.06	0.83
Return ratios
Return on assets %	9.8%	16.6%	9.9%
Return on capital employed %	15.7%	24.5%	18.5%
Return on equity %	13.1%	20.7%	14.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	70.17%	70.17%	70.17%	70.17%	70.17%	70.17%	70.17%	70.17%	70.17%	70.17%	68.29%	68.29%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.18%	0.01%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	29.83%	29.83%	29.83%	29.83%	29.83%	29.83%	29.83%	29.83%	29.83%	29.83%	31.53%	31.7%
No. of shareholders	—	—	—	—	—	—	—	—	4,130	4,738	4,531	4,690

Promoter holding down 1.88 percentage points since Sep 2023.

2 deals · 12 Jul 2022 – 6 Mar 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
6 Mar 2026	SHAH DALPATLAL NITIN	Bulk	NSE	Sell	1,38,661	₹114.18	₹1.58 Cr
12 Jul 2022	SHALIN SHAH .	Bulk	BSE	Buy	37,500	₹77.77	₹0.29 Cr

1–2 of 2

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Rinku Dipenbhai JethvaChief Financial Officer
Mr. Jagdish AjudiaExecutive Director-Chairperson-CEO-MD
Mrs. Maltiben AjudiaExecutive Director
Ms. Priyanka AjudiaExecutive Director
Mrs. Shilpa ThumarNon-Executive - Independent Director
Mrs. Ritaben Nileshbhai KikaniNon-Executive - Independent Director
Mrs. Hemanshi Darsh SoniNon-Executive - Independent Director
Ms. Dimpy JoshiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Indo Us Biotech Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

9

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

2

Interim dividend3 Dec 2024 · ex-date₹0.25
Interim dividend28 Oct 2021 · ex-date₹0.25

1

Board meeting to consider results12 Aug 2026

3

Bonus 1:129 Aug 2023 · ex-date
Bonus 1:529 Nov 2021 · ex-date
Bonus 1:423 Apr 2019 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

60 announcementsExport CSV

30 Sept 2026, 6:39 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

28 Sept 2026, 10:47 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

6 Sept 2026, 8:55 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

5 Sept 2026, 3:33 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

5 Sept 2026, 3:20 pmAGM/EGM

Intimation Of Book Closure For The Purpose Of 22Nd AGM Pursuant To Regulation 42 Of SEBI (LODR)

AGM PDF

5 Sept 2026, 3:10 pmAGM/EGM

Shareholder Meeting- AGM On Sep 30, 2026

AGM PDF

5 Sept 2026, 2:57 pmOthers

Board Meeting Outcome for Outcome Of The Board Meeting Held On Saturday, 05Th September, 2026.

Outcome without intimation PDF

15 Jul 2026, 4:24 pmCompany Update

Revised Outcome Of The Board Meeting Held On 10 July 2026. Reconstitution Of Committees.

General PDF

Date	Category	Subject	Filing
30 Sept 2026, 6:39 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
28 Sept 2026, 10:47 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Indo Us Biotech Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends2

Board meetings1

Bonus issues3

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Dividends2

Board meetings1

Bonus issues3

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

2

1

3

2

1

3